Reimagining the future of Huntington’s disease

SOPHIA Huntington’s Disease Community Advocate

Home hero advocate sophia 2

Press Releases

Sep 29, 2026
uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression
Sep 2, 2026
uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease
Jul 29, 2026
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

See All